Supplementary Tables – Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy

   Sensitivity analysis 1: Statistical adjustment without inverse probability of treatment weighting (IPTW)    Sensitivity analysis 2: Censoring patients in the practice subanalysis who initiate a therapy off-sequence    Sensitivity analysis 3: Restricting to CPI patients receiving ipilimumab + nivolumab    Supplemental Table 1. Comparison of statistical adjustments with and without inverse probability of treatment weighting (IPTW).    Supplemental Table 2. Baseline Characteristics of Patients With Advanced BRAF-Mt Melanoma by 1L Treatment</p

Supplementary Figures – Real-world treatment patterns and overallsurvival in BRAF-mutant melanoma patientstreated with immunotherapy or targetedtherapy

   Supplemental Figure 1. Kaplan-Meier Estimates of Overall Survival (OS) in Patients With Advanced BRAF-Mt Melanoma Receiving 1L Treatment With CPI (ipilimumab/nivolumab) or TT.    Supplemental Figure 2. Kaplan-Meier estimates of Overall Survival (OS) in Patients With Advanced BRAF-Mt Melanoma Receiving 1L Treatment With CPI (ipilimumab/nivolumab) or TT weighted by IPTW.</p

S1 Data -

(PDF)</p

Criteria for assessment of complete response.

Abbreviations: BCC, basal cell carcinoma. Vismodegib = received vismodegib within 90 days of diagnosis; non-vismodegib treatment = received interventions other than vismodegib within 90 days of diagnosis; Observation = received no intervention within 90 days of diagnosis. (PDF)</p

Baseline disease characteristics in patients with locally advanced basal cell carcinoma in Cohort 1.

Baseline disease characteristics in patients with locally advanced basal cell carcinoma in Cohort 1.</p

Parameters used to determine response assessment.

Abbreviations: BCC, basal cell carcinoma; laBCC, locally advanced basal cell carcinoma; mBCC, metastatic basal cell carcinoma. Vismodegib = received vismodegib within 90 days of diagnosis; non-vismodegib treatment = received interventions other than vismodegib within 90 days of diagnosis; Observation = received no intervention within 90 days of diagnosis. (PDF)</p

Methodology used for disease assessment.

Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging. Vismodegib = received vismodegib within 90 days of diagnosis; non-vismodegib treatment = received interventions other than vismodegib within 90 days of diagnosis; Observation = received no intervention within 90 days of diagnosis. (PDF)</p

Baseline demographics in patients with locally advanced basal cell carcinoma in Cohort 1.

Baseline demographics in patients with locally advanced basal cell carcinoma in Cohort 1.</p

Basal cell carcinoma.

Representative treatment patterns among randomly selected patients treated within the first 90 days with vismodegib (n = 40, A), non-vismodegib treatment (n = 40, B), and observation (n = 28, C). Vismodegib = received vismodegib within 90 days of diagnosis; non-vismodegib treatment = received interventions other than vismodegib within 90 days of diagnosis; observation = received no intervention within 90 days of diagnosis. Bar lengths represent duration from date of locally advanced basal cell carcinoma diagnosis to study termination, death, or data cutoff; > denotes death; X denotes initial progression; * denotes surgery.</p

Health insurance coverage, history of psychiatric disorders/dementia, and BCC treatment history in patients with locally advanced basal cell carcinoma in Cohort 1.

Abbreviations: BCC, basal cell carcinoma; laBCC, locally advanced basal cell carcinoma. aSpecific diagnoses occurring in 2 or more patients are reported. Vismodegib = received vismodegib within 90 days of diagnosis; non-vismodegib treatment = received interventions other than vismodegib within 90 days of diagnosis; observation = received no intervention within 90 days of diagnosis. (PDF)</p